← Back to Search

Monoclonal Antibodies

KN026 for Gastric Cancer

Phase 1
Waitlist Available
Research Sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial is testing a new drug, KN026, to see if it is safe and works well against HER2 positive advanced breast and gastric cancer.

Eligible Conditions
  • Gastric Cancer
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

1Treatment groups
Experimental Treatment
Group I: KN026Experimental Treatment1 Intervention
Patient will be intravenously administrated with one dose of KN026. Dosing interval may be adjusted during the study based on emerging data from this trial and/or from other trial.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
KN026
2018
Completed Phase 1
~70

Find a Location

Who is running the clinical trial?

Jiangsu Alphamab Biopharmaceuticals Co., LtdLead Sponsor
26 Previous Clinical Trials
2,979 Total Patients Enrolled
~4 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top